Why the study?
Pulmonary arterial hypertension continues to carry high morbidity and mortality despite 30 years of progress, while recent pharmacological and technological advances have introduced novel treprostinil formulations and delivery routes.
This review highlights recent pharmacological and technological advances in treprostinil administration for pulmonary arterial hypertension, emphasizing novel delivery routes and improved affordability through generic availability.
May expand treprostinil access and convenience in PAH; leaves open comparative efficacy and outcome data.
Despite progress over the past 30 years, pulmonary arterial hypertension remains a condition with high morbidity and mortality. Pharmacological and technological advances have shifted the approach to treating pulmonary arterial hypertension. Recent developments revolve heavily around novel routes of drug administration and delivery. In 2009, inhaled treprostinil was approved followed by oral treprostinil in 2013 providing patients with more convenient routes of administration compared with the parenteral alternatives. We are on the cusp of having the first fully implantable infusion pump for continuous intravenous treprostinil delivery. In 2019, generic treprostinil was approved, making the medication much more affordable for patients. In this review, we discuss in detail the recent developments surrounding both traditional and novel treprostinil products.
No takes yet. Share an insight, caveat, or question.
Feldman et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: